The short-term outcomes of lupus nephritis (LN) are variable and unpredictable among individuals. We aimed to evaluate the clinical and histopathological features and short-term renal outcomes in LN patients.
Methods
This was a prospective cohort study carried out at nephrology and rheumatology units in Egypt between 2018 and 2019. A total of 100 patients with biopsy-proven LN were studied. Patients were evaluated for response after six months.
Results
The female-to-male ratio was 8.1:1. About 70% of patients were hypertensive at disease onset, with rates for classes I, II, III, IV, V and VI LN being 1%, 7%, 20%, 53%, 14% and 6%, respectively. Among the immunosuppressive drugs used for induction, mycophenolate mofetil (MMF) represented the most commonly used (44%) followed by cyclophosphamide (CYC; 37%). After six months of follow-up, about two thirds of patients achieved remission. There was no significant difference in remission rate between MMF and CYC. On multivariate analysis, serum creatinine (SCr) at presentation was the most significant predictor of renal recovery. According to the receiver operating characteristic curve, the cut-off value of SCr was 1.6 mg/dL, with a sensitivity of 76% and specificity of 71% predicting renal recovery. Repeat renal biopsy was needed in 10 patients; class and treatment strategy changed in 40% and 70% of them, respectively.
Conclusion
Our findings in Egyptian LN patients compare favourably with most studies.
KarimzadehHShirzadiMKarimifarM.The effect of vitamin D supplementation in disease activity of systemic lupus erythematosus patients with vitamin D deficiency: a randomized clinical trial. J Res Med Sci2017;
22: 4.
2.
DörnerTFurieR.Novel paradigms in systemic lupus erythematosus. Lancet2019;
393: 2344–2358.
3.
HaładyjECerveraR.Do we still need renal biopsy in lupus nephritis?Reumatologia2016;
54: 61.
4.
RovinBHParikhSVAlvaradoA.The kidney biopsy in lupus nephritis: is it still relevant?Rheum Dis Clin2014;
40: 537–552.
5.
RovinBHParikhSV.Lupus nephritis: the evolving role of novel therapeutics. Am J Kidney Dis2014;
63: 677–690.
6.
HsuCChiuWYangT, et al.
Age-and gender-related long-term renal outcome in patients with lupus nephritis. Lupus2011;
20: 1135–1141.
7.
Dall’EraMCisternasMGSmilekDE, et al.
Predictors of long‐term renal outcome in lupus nephritis trials: lessons learned from the Euro‐Lupus Nephritis cohort. Arthritis Rheum2015;
67: 1305–1313.
8.
SircarDSircarGWaikhomRRaychowdhuryAPandeyR.Clinical features, epidemiology, and short-term outcomes of proliferative lupus nephritis in Eastern India. Indian J Nephrol2013;
23: 5.
9.
KoubarSHKortJKawtharaniSChaayaMMakkiMUthmanI.Characteristics of lupus and lupus nephritis at a tertiary care center in Lebanon. Lupus2019;
28: 1598–1603.
10.
MahmoudGZayedHGhoniemS.Renal outcomes among Egyptian lupus nephritis patients: a retrospective analysis of 135 cases from a single centre. Lupus2015;
24: 331–338.
11.
MomtazMFayedAWadieM, et al.
Retrospective analysis of nephritis response and renal outcome in a cohort of 928 Egyptian lupus nephritis patients: a university hospital experience. Lupus2017;
26: 1564–1570.
12.
HochbergMC.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997;
40: 1725.
13.
PetriMOrbaiAMAlarcónGS, et al.
Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012;
64: 2677–2686.
14.
LeveyASBoschJPLewisJBGreeneTRogersNRothD. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med1999;
130: 461–470.
15.
WeeningJJD’AgatiVDSchwartzMM, et al.
The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol2004;
15: 241–250.
16.
CattranDCFeehallyJCookHT, et al.
Kidney Disease: Improving Global Outcomes (KDIGO) glomerulonephritis work group. KDIGO clinical practice guideline for glomerulonephritis.Kidney Int Suppl2012;
2: 139–274.
17.
Almaani S, Meara A and Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol 2017; 12: 825–835.
18.
LimCCTanHZHaoY, et al.
Long-term renal outcomes in multi-ethnic Southeast Asians with lupus nephritis: a retrospective cohort study. Intern Med J2018;
48: 1117–1123.
19.
Al ArfajASKhalilNAl SalehS.Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia. Rheumatol Int2009;
29: 1057–1067.
20.
AyodeleOEOkpechiIGSwanepoelCR.Predictors of poor renal outcome in patients with biopsy-proven lupus nephritis. Nephrology (Carlton)2010;
15: 482–490.
21.
SatirapojBTasanavipasPSupasyndhO.Clinicopathological correlation in Asian patients with biopsy-proven lupus nephritis. Int J Nephrol2015;
2015: 857316.
22.
IsmailMILakouzKAbdelbaryE.Clinicopathological correlations of renal pathology: a single center experience.Saudi J Kidney Dis Transplant2016;
27: 557–562.
23.
ContrerasGPardoVCelyC, et al.
Factors associated with poor outcomes in patients with lupus nephritis. Lupus2005;
14: 890–895.
24.
MaxwellSRMootsRJKendallMJ.Corticosteroids: do they damage the cardiovascular system?Postgrad Med J1994;
70: 863–870.
25.
RyanMJMcLemoreGRJr.Hypertension and impaired vascular function in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comp Physiol2007;
292: R736–R42.
26.
NakanoMUenoMHasegawaH, et al.
Renal haemodynamic characteristics in patients with lupus nephritis. Ann Rheum Dis1998;
57: 226–230.
27.
HaddiyaIHamzaouiHTachfoutiN, et al.
Features and outcomes of lupus nephritis in Morocco: analysis of 114 patients. Int J Nephrol Renovasc Dis2013;
6: 249.
28.
BéjiSKaaroudHMoussaFB, et al.
Néphropathie lupique: à propos de 211 cas.Rev Med Interne2005;
26: 8–12.
29.
ResendeALTitanSMBarrosRTWoronikV.Worse renal outcome of lupus nephritis in male patients: a case-control study. Lupus2011;
20: 561–567.
30.
MahmoudGShahinAZayedHMoghazyAEissaB.Clinical and immunological pattern and outcome of Egyptian systemic lupus erythematosus patients: a single center experience. Lupus2018;
27: 1562–1569.
31.
SircarDSircarGWaikhomRRaychowdhuryAPandeyR.Clinical features, epidemiology, and short-term outcomes of proliferative lupus nephritis in Eastern India. Indian J Nephrol2013;
23: 5–11.
32.
DavidsonJEFuQJiB, et al.
Renal remission status and longterm renal survival in patients with lupus nephritis: a retrospective cohort analysis. J Rheumatol2018;
45: 671–677.
33.
ContrerasGPardoVCelyC, et al.
Factors associated with poor outcomes in patients with lupus nephritis. Lupus2005;
14: 890–895.
34.
ChanTMLiFKTangCS, et al.
Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. New Engl J Med2000;
343: 1156–1162.
35.
ChanT-MTseK-CTangCS-OMokM-YLiF-K.Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol2005;
16: 1076–1084.
36.
GoswamiRPSircarGSitHGhoshAGhoshP.Cyclophosphamide versus mycophenolate versus rituximab in lupus nephritis remission induction: a historical head-to-head comparative study. J Clin Rheumatol2019;
25: 28–35.
37.
HuWLiuZChenH, et al.
Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.Chin Med J (Engl)2002;
115: 705–709.
38.
AppelGBContrerasGDooleyMA, et al.
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol2009;
20: 1103–1112.
39.
ElliottJRManziS.Induction therapy for active lupus nephritis: mycophenolate mofetil is superior to cyclophosphamide. Nat Clin Pract Rheumatol2006;
2: 354–355.
40.
BurchardiCSchlöndorffD.Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide. Nat Clin Pract Nephrol2006;
2: 314–315.
41.
MahmoodNMahmoodFShumiSISiddiquiMMR.Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. Anwer Khan Mod Med Coll J2018;
9: 63–67.
42.
LeveyALanSCorwinH, et al.
Lupus Nephritis Collaborative Study Group: progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide. Ann Intern Med1992;
116: 114–123.
43.
FraenkelLMacKenzieTJosephLKashgarianMHayslettJEsdaileJ.Response to treatment as a predictor of longterm outcome in patients with lupus nephritis. J Rheumatol1994;
21: 2052–2057.
44.
AppelGBCohenDJPiraniCLMeltzerJIEstesD.Long-term follow-up of patients with lupus nephritis: a study based on the classification of the World Health Organization.Am J Med1987;
83: 877–885.
45.
AustinIIIHBoumpasDVaughanEBalowJ.High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients.Nephrol Dial Transplant1995;
10: 1620–1628.
46.
AustinIII HAMuenzLRJoyceKMAntonovychTTBalowJE.Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int1984;
25: 689–695.
47.
TamirouFLauwerysBRDall’EraM, et al.
A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus Sci Med2015;
2: e000123.
48.
MoroniGPasqualiSQuagliniS, et al.
Clinical and prognostic value of serial renal biopsies in lupus nephritis.Am J Kidney Dis1999;
34: 530–539.
49.
GreloniGScolnikMMarinJ, et al.
Value of repeat biopsy in lupus nephritis flares. Lupus Sci Med2014;
1: e000004.
50.
NarváezJRicseMGomàM, et al.
The value of repeat biopsy in lupus nephritis flares.Medicine (Baltimore)2017;
96: e7099.
